SCHEMBL1801548

SCHEMBL1801548

CCc1sc(C(C)=O)cc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.46
C1S P09871 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.40
PLK1 P53350 1/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
HTT P42858 1/20 0.40
MAPK14 Q16539 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
BACE1 P56817 1/20 0.37
USP47 Q96K76 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1802291 0.89 PLAU (0.47) PLAUC1SL3MBTL1PLK1RAB9A
SCHEMBL1801983 0.86 MAPK14 (0.42) PLAUC1SMAPTSMN1; SMN2RAB9A
SCHEMBL2323109 0.83 L3MBTL1 (0.53) PLAUC1SL3MBTL1PLK1MAPT
SCHEMBL1797641 0.81 RAB9A (0.44) PLAUC1SL3MBTL1MAPTSMN1; SMN2
SCHEMBL1801707 0.78 PLK1 (0.43) PLAUC1SPLK1MAPTSMN1; SMN2
SCHEMBL1798929 0.75 BCHE (0.43) PLAUC1SL3MBTL1MAPTSMN1; SMN2
SCHEMBL1798930 0.75 BCHE (0.43) PLAUC1SL3MBTL1MAPTSMN1; SMN2
SCHEMBL10088519 0.75 CYP2A6 (0.42) PLAUC1SL3MBTL1MAPTSMN1; SMN2
SCHEMBL1801565 0.74 S1PR1 (0.39) PLAUC1SL3MBTL1MAPTNPC1
SCHEMBL12441421 0.74 ALOX5 (0.40) PLAUC1SL3MBTL1PLK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951794-B2 Thiophene derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-31 US disclosed
US-20100075946-A1 NOVEL THIOPHENE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-03-25 US disclosed
EP-1896446-A1 NOVEL THIOPHENE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-12 EP disclosed
WO-2006137019-A1 NOVEL THIOPHENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075946-A1 NOVEL THIOPHENE DERIVATIVES TPMT, TSLP, NFATC1 PLAU 4771/4885C1S 3899/4885L3MBTL1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.